|
|
|
|
|
|||||||
|
Session 77
Poster Session
Resistance Testing in Drug Selection 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 580-T. | Incidence and Nature of Phenotype-Genotype Discordance: Maximizing the Utility of Resistance Testing N. T. Parkin*1, C. Chappey1, L. Maroldo1, J. Arocha2, T. Fralich3, S. Schrader4, D. Ward5, M. Wohlfeiler6 , and M. Bates1 1ViroLogic, Inc., South San Francisco, CA; 2Miami, FL; 3Ft. Lauderdale, FL; 4Southampton Med. Group, Houston, TX; 5Dupont Circle Physicians Group, Washington, DC; and 6Wohlfeiler, Piperato and King, Miami, FL
| ||
| 581-T. | Relationship Between Lopinavir (LPV) Susceptibility and HIV-1 Protease Genotype N. T. Parkin*, C. Chappey, and C. J. Petropoulos ViroLogic, South San Francisco, CA
| ||
| 582-T. | Structural Phenotype Predicts HIV-1 Protease Inhibitor Resistance M. Shenderovich*1, R. Kagan2, K. Ramnarayan1, P. Hess2, and P. Heseltine2 1Structural Bioinformatics Inc., San Diego, CA and2 Quest Diagnostics, San Juan Capistrano, CA
| ||
| 583-T. | Effects of Human Serum on Protease Inhibitor Activity in a Phenotypic Drug Susceptibility Assay (PhenoSense HIV) K. Limoli*, L. H. Trinh, G. M. Heilek-Snyder, N. S. Hellmann, and C. J. Petropoulos ViroLogic Inc., South San Francisco, CA
| ||
| 584-T. | Meta-Analysis of Antiretroviral Drug Resistance Testing in HIV-1 Infection D. Torre* and R. Tambini Regional Hosp. and Macchi Fndn., Varese, Italy
| ||
| 585-T. | GENOPHAR: A Randomized Study of Plasmatic Drug Measurements Associated with Genotypic Resistance Testing in Patients Failing Antiretroviral Therapy P. Bossi*1, G. Peytavin2, C. Delaugerre1, D. J. David3, M. Bonmarchand1, R. Cacace1, N. Kortza1, H. Ait Mohand1, A. Simon1, C. Laroche2, V. Calvez1, F. Bricaire1, D. Costagliola3, and C. Katlama1 1Pitié-Salpêtrière Hosp.; 2Bichat Hosp.; and 3INSERM SC44, Paris, France
| ||
| 586-T. | A Randomized, Prospective Study of Phenotype (P) versus Virtual Phenotype (VirtualP) Testing for Patients Failing Antiretroviral Therapy (ART) M. J. Perez-Elias1, I. Garcia-Arata1, V. Muñoz1, I. Santos*2, J. Sanz1, 3, V. Abraira, A. Moreno1, J. R. Arribas4, J. González4 , A. Antela1, F. Dronda1, M. Pumares1, P. Martí-Belda1, and S. Moreno1 for the Realvirfen Study Group 1Hosp. Ramón y Cajal, Madrid; 2Hosp. de La Princesa, Madrid; 3Hosp. Príncipe de Asturias, Alcalá de Henares; and 4Hosp. La Paz, Madrid, Spain
| ||
| 587-T. | CREST-- A Randomised Comparison of 2 Resistance Test Platforms: Genotype and Virtual Phenotype C. Workman*1, G. Hales2, P. McKenna3, and for the CREST Study Group 1Ground Zero Med. Ctr., Sydney, Australia; 2NCHECR, Sydney, Australia; and 3 Virco, Mechelen, Belgium
| ||
| 588-T. | Genotype, Phenotype, and Virtual Phenotype at Baseline and at Failure in Naïve Patients Included in a Randomized Trial (Rescombine Study) E. Ferrer*1, D. Podzamczer1, M. Arnedo2, E. Fumero1, J. L. Perez1, M. J. Barbera1, T. Pumarola2, and J. M. Gatell2 1Hosp. Bellvitge and 2Hosp. Clin.. Barcelona, Spain
| ||
| 589-T. | Real vs VirtualPhenotype: 12-Month Results from the GenPherex Study F. Mazzotta*1, S. Lo Caputo1, C. Torti1, C. Tinelli3, F. Castelli2, P. Pierotti1, G. Angarano4, L. Sighinolfi5, A. Poggio6, N. Gianotti7, R. Maserati3, M. De Gennaro8, A. Vivarelli9, P. DelleFoglie10, and G. Carosi2 for the GenPherex Group 1S. M. Annunziata Hosp., Florence; 2Univ. of Brescia; 4Univ. of Foggia; 5Hosp. of Ferrara; 3Univ. of Pavia; 6Hosp. of Verbania; 7San Raffaele Hosp., Milano; 8Hosp. of Lucca; 9Hosp. of Pistoia; and 10Hosp. of Trento, Italy
| ||
| 590-T. | Head-to-Head Comparison of Widely Used HIV-1 Drug Resistance Algorithms: RetroGram and VGI-TRUGENE HIV-1 C. Torti*1 , E. Quiros-Roldan1 , C. A. B. Boucher 2 , C. Tinelli3, A. M. M. Been-Tiktak4 , S. Lo Caputo5, F. Mazzotta5, F. Castelli1, L. Tomasoni1, S. Day6, and G. Carosi1 1Univ. of Brescia, Italy; 2Univ. Med. Ctr., Utrecht, The Netherlands; 3IRCCS PoliClinic S. Matteo, Pavia, Italy; 4 Virology Networks, Utrecht, The Netherlands; 5 ASL Firenze, Italy; and 6Visible Genetics, London, UK
| ||
| 591-T. | Baseline Phenotypic Susceptibility and Virologic Failure over 144 Weeks among Nucleoside RT Inhibitor Experienced Subjects in ACTG 364 D. Katzenstein*1, R. J. Bosch2, N. Wang2, N. S. Hellmann3, L. Bacheler4, and M. Albrecht5 for the ACTG 364 Study Team 1Stanford Univ, CA; 2Harvard Sch. Publ. Hlth., Boston, MA; 3ViroLogic Inc., South San Francisco, CA; 4Bristol-Myers Squibb, Wilmington, DE; and 5Beth Israel Deaconess Med. Ctr., Boston, MA
| ||
| 592-T. | Alternative Phenotypic Sensitivity Scores and Outcome Measures Increase Detection of the Impact of Drug Resistance on Response to Salvage Therapy -- Results from ACTG 359 R. Swanstrom*1, H. Cheng2, N. S. Hellmann3, D. Katzenstein4, R. J. Bosch2, S. A. Fiscus1, R. Haubrich5, and R. Gulick6 1Univ. of North Carolina, Chapel Hill; 2 Harvard Sch. of Publ. Health, Boston, MA; 3ViroLogic, Inc., South San Francisco, CA; 4Stanford Univ. Med. Ctr., Palo Alto, CA; 5Univ. of California, San Diego; and 6Weill Med. Coll. of Cornell Univ., New York, NY
| ||
| 593-T. | Prognostic Significance of HIV-1 Resistance Tests Is Enhanced by Consideration of Mutiple Test Results D. Pillay*1,2, S. Mandalia1, C. Torti1, B. Gazzard1, and A. Pozniak1 1Chelsea and Wetminster Hosp., London and 2Univ. of Birmingham Med. Sch., UK
|
